Suturing Distance From the Wound Edge, 2 mm vs 5 mm
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03330041 |
Recruitment Status :
Completed
First Posted : November 6, 2017
Results First Posted : January 21, 2020
Last Update Posted : May 12, 2021
|
Sponsor:
University of California, Davis
Information provided by (Responsible Party):
University of California, Davis
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Single Group Assignment; Masking: Single (Outcomes Assessor); Primary Purpose: Other |
Condition |
Cutaneous Sutures and Scar Cosmesis |
Intervention |
Device: Fast absorbing gut suture |
Enrollment | 50 |
Participant Flow
Recruitment Details | This randomized clinical trial was conducted at the University of California, Davis dermatology clinic from November 28, 2017, to June 15, 2018. |
Pre-assignment Details |
Arm/Group Title | All Participants |
---|---|
![]() |
A split wound model was used, where half of the wound was repaired with sutures placed 2 millimeters apart and the other half is repaired with sutures placed 5 millimeters apart. A predetermined, concealed randomization number was obtained from the RedCap randomization module, which specified how Side A was treated. Side B was treated the opposite way as A. |
Period Title: Overall Study | |
Started | 50 |
Completed | 48 |
Not Completed | 2 |
Baseline Characteristics
Arm/Group Title | Fast Absorbing Gut Suture Placed 2 mm and 5 Mmapart | |
---|---|---|
![]() |
Wound closed with sutures spaced 2 and 5 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern Fast absorbing gut suture: Fast absorbing surgical gut suture is a strand of collagenous material |
|
Overall Number of Baseline Participants | 50 | |
![]() |
[Not Specified]
|
|
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||
Number Analyzed | 50 participants | |
71.1 (11.4) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 50 participants | |
Female |
7 14.0%
|
|
Male |
43 86.0%
|
|
Race (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 50 participants | |
American Indian or Alaska Native |
0 0.0%
|
|
Asian |
0 0.0%
|
|
Native Hawaiian or Other Pacific Islander |
0 0.0%
|
|
Black or African American |
0 0.0%
|
|
White |
50 100.0%
|
|
More than one race |
0 0.0%
|
|
Unknown or Not Reported |
0 0.0%
|
|
Region of Enrollment
Measure Type: Number Unit of measure: Participants |
||
United States | Number Analyzed | 50 participants |
50 |
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Results Point of Contact
Name/Title: | Daniel Eisen, M.D. |
Organization: | University of California, Davis, Department of Dermatology |
Phone: | 916-734-6479 |
EMail: | dbeisen@ucdavis.edu |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | University of California, Davis |
ClinicalTrials.gov Identifier: | NCT03330041 |
Other Study ID Numbers: |
1115596 |
First Submitted: | October 26, 2017 |
First Posted: | November 6, 2017 |
Results First Submitted: | October 22, 2019 |
Results First Posted: | January 21, 2020 |
Last Update Posted: | May 12, 2021 |